Loading
Allogene Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 06 Mar 2024.
Allogene Therapeutics, Inc.: what insiders have been doing
Allogene Therapeutics, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 8 insiders have disclosed 17 filings since 18 October 2025.
Only sales appear on the open market, 14 sales in all totalling €515k, filed by 6 insiders. The largest single trade was a sale of €145k by Chang David D, published on 4 February 2026.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (5,458 companies, median 22 filings), a count of 17 filings is below the norm. Over the whole record (from 2021), the tally stands at 3 purchases and 49 sales. The 10-K for the year ended 31 December 2025 shows -190.9 m USD of net income.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
127
Thresholds
n/a
Buy Volume
€2M
3 ops. · all time
Sell Volume
€3M
49 ops. · all time
Who traded when
BuySaleBenjamin Machinas Beneski6 sales
David D. Chang4 sales
Zachary Roberts4 sales
Annie Yoshiyama3 sales
Deborah M. Messemer3 sales
Geoffrey M. Parker3 sales
+3 other insiders
Since the insiders bought
- -41.0%Entry US$11.78 · Close at T+365 US$6.95
- -41.0%Entry US$11.78 · Close at T+365 US$6.95
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.30
Analyst consensus
9 analysts1.42/5
US$4.00Target US$9.00(+592%)US$14.00
Income statement
EBITDA-US$177.5M
Net income-US$190.9M0.0% margin
Valuation
PER (forward)-2.1x
P/Book1.0x
Beta0.56
Balance sheet & cash
Market capUS$449.1M
Total debtUS$83.3M
Free Cash Flow-US$149.6M
Debt / Equity18%
Profitability & ownership
ROE-42.4%
ROA-22.1%
% insiders11.0%
% institutions82.7%
Last declaration on 21 August 2026
Declarations127 total
29,697 shares@ US$2.120.011% mcap39.8% of flowCommon StockSEC144:0001737287-26-000023
47,700 sharesCommon StockSEC:0001221355-26-000002:0
9,586 shares@ US$2.310.0030% mcap75.7% of flowCommon StockSEC:0001835208-26-000003:0
2,867 shares@ US$2.5038.3% of flowCommon StockSEC:0002057918-26-000007:0
4,835 shares@ US$2.4727.4% of flowCommon StockSEC:0001737287-26-000015:0
47,763 shares@ US$2.4741.6% of flowCommon StockSEC:0001737287-26-000013:0
7,132 shares@ US$2.6041.4% of flowCommon StockSEC:0002057918-26-000003:0
35,700 shares@ US$1.7760.4% of flowCommon StockSEC:0001737287-26-000002:0
7,549 shares@ US$1.7329.0% of flowCommon StockSEC:0001737287-26-000011:0
24,001 shares@ US$1.7647.2% of flowCommon StockSEC:0001737287-26-000007:0
4,167 shares@ US$1.7224.3% of flowCommon StockSEC:0001737287-26-000005:0
22,900 shares@ US$1.76100.0% of flowCommon StockSEC:0001362155-26-000002:0
95,269 shares@ US$1.8058.4% of flowCommon StockSEC:0001737287-26-000009:0
26,269 shares@ US$1.5639.6% of flowCommon StockSEC:0001851044-26-000003:0
47,700 shares0Common StockSEC:0001221355-25-000005:0
786 shares@ US$1.222.2% of flowCommon StockSEC:0001737287-25-000094:0
36,744 shares@ US$1.256552.8% of flowCommon StockSEC:0001737287-25-000091:0
36,885 shares@ US$1.42100.0% of flowCommon StockSEC:0001737287-25-000066:0
9,601 shares@ US$1.41100.0% of flowCommon StockSEC:0001835208-25-000007:0
5,488 shares@ US$1.97561.7% of flowCommon StockSEC:0001737287-25-000040:0
46,668 shares@ US$1.964.3% of flowCommon StockSEC:0001737287-25-000042:0
31,755 shares0Common StockSEC:0001737287-25-000026:0
13,313 shares@ US$2.4322.8% of flowCommon StockSEC:0001737287-25-000022:0
46,003 shares@ US$1.683.8% of flowCommon StockSEC:0001737287-25-000017:0
4,361 shares@ US$1.730.7% of flowCommon StockSEC:0001737287-25-000019:0
25 of 127 declarations
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a U.S.-based biotechnology company listed on the Nasdaq market in the United States, with headquarters in South San Francisco, California. The company focuses on allogeneic CAR T-cell therapies, meaning “off-the-shelf” cell therapies made from donor cells rather than the patient’s own cells. Its strategic focus is primarily oncology, with an expanding interest in autoimmune disease, placing Allogene in one of the most scientifically ambitious areas of modern immuno-oncology. ([ir.allogene.com](https://ir.allogene.com/?utm_source=openai))
Founded in 2017, Allogene was built around deep cell-therapy and clinical-development expertise. The company does not yet have an approved commercial product and remains a clinical-stage biotech, which means revenue generation is still limited and value creation depends heavily on clinical execution, regulatory progress, and the strength of its balance sheet. The underlying investment case is tied to whether a standardized allogeneic CAR T platform can overcome some of the structural limitations of autologous CAR-T therapies, especially around manufacturing time, logistics, and access. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1737287/000173728725000051/allo-20241231x10k.pdf?utm_source=openai))
Read moreShow less
Allogene’s pipeline centers on cema-cel (cemacabtagene ansegedleucel) and several additional allogeneic product candidates targeting different hematologic cancers and autoimmune indications. The company’s core thesis is that an “off-the-shelf” CAR T platform could deliver faster availability, more predictable manufacturing, and potentially more scalable economics than patient-specific cell therapies. From a competitive standpoint, Allogene operates in a crowded and highly innovative field that includes large pharmaceutical companies and specialized biotech peers pursuing CAR-T, engineered cell therapies, and next-generation immunology approaches. Its differentiation lies in being one of the more focused pure-play developers of allogeneic CAR-T technology. ([ir.allogene.com](https://ir.allogene.com/?utm_source=openai))
Geographically, the business is centered in the United States, although the company is extending trial activity and collaboration footprints beyond its home market. Recent highlights include a public equity offering announced in April 2026, expansion of the pivotal ALPHA3 trial to South Korea and Australia, and a stream of clinical and financial updates in 2026 as management positions the year as a key inflection period. For investors, Allogene remains a high-risk, high-upside development-stage biotech story on Nasdaq, with the share performance likely to remain highly sensitive to clinical readouts, cash runway, and execution against its allogeneic CAR-T roadmap. ([ir.allogene.com](https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-announces-pricing-public-offering-common-0?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
